Pharsight

1. Adrenalin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119876	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)
US10130592	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)
US9295657	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL ampules	09 Mar, 2016	1	06 Jul, 2018	13 Mar, 2035	Deferred
30 mg/30 mL	20 Aug, 2018	1	24 Apr, 2020	13 Mar, 2035	Eligible

Strength	Dosage	Availability
EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	Prescription

ADRENALIN family patents

2. Epinephrine In 0.9 Percent Sodium Chloride patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083698	PAR STERILE PRODUCTS	Epinephrine compositions and containers	Mar, 2039 (15 years from now)
US10653646	PAR STERILE PRODUCTS	Epinephrine compositions and containers	Mar, 2039 (15 years from now)
US11207280	PAR STERILE PRODUCTS	Epinephrine compositions and containers	Mar, 2039 (15 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 21 April, 2023

Treatment: To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
2MG/250ML (8MCG/ML)	SOLUTION;INTRAVENOUS	Prescription
4MG/250ML (16MCG/ML)	SOLUTION;INTRAVENOUS	Prescription
5MG/250ML (20MCG/ML)	SOLUTION;INTRAVENOUS	Prescription
8MG/250ML (32MCG/ML)	SOLUTION;INTRAVENOUS	Prescription
10MG/250ML (40MCG/ML)	SOLUTION;INTRAVENOUS	Prescription

EPINEPHRINE IN 0.9 PERCENT SODIUM CHLORIDE family patents

3. Vasostrict patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919026	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9981006	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9974827	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9968649	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9962422	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9925234	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9925233	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9687526	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9750785	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9375478	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9744209	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9937223	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US9744239	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)
US10010575	PAR STERILE PRODUCTS	Vasopressin formulations for use in treatment of hypotension	Jan, 2035 (11 years from now)

Drugs and Companies using VASOPRESSIN ingredient

Market Authorisation Date: 17 April, 2014

Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines

Dosage: SOLUTION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 units/mL, 1 mL	23 Mar, 2018	1	15 Dec, 2021	30 Jan, 2035	Non-Forfeiture Deferred
200 units/10 mL	29 Jun, 2018	1		30 Jan, 2035	Non-Forfeiture
20 units/100 mL	20 Dec, 2022	1		30 Jan, 2035
40 units/100 mL and 60 units/100 mL	28 Feb, 2022	1		30 Jan, 2035

Strength	Dosage	Availability
20UNITS/ML (20UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription
20UNITS/100ML (0.2UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription
40UNITS/100ML (0.4UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription
60UNITS/100ML (0.6UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription
200UNITS/10ML (20UNITS/ML)	SOLUTION;INTRAVENOUS	Prescription